Anastomotic recurrence of Crohn’s disease after ileocolic resection: comparison of MR enteroclysis with endoscopy

被引:0
作者
Johannes Sailer
Philipp Peloschek
Walter Reinisch
Harald Vogelsang
Karl Turetschek
Wolfgang Schima
机构
[1] Medical University of Vienna,Department of Radiology
[2] Medical University of Vienna,Department of Internal Medicine III, Division of Gastroenterology
[3] Diagnosezentrum Favoriten,undefined
来源
European Radiology | 2008年 / 18卷
关键词
MR enteroclysis; Crohns disease; Recurrence; Ileocolic resection;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study was to assess the accuracy of MR enteroclysis in patients with Crohn’s disease recurrence after ileocolic resection and to establish an MR scoring sytem. MR enteroclysis and endoscopy were performed in 30 patients with suspected Crohn’s disease recurrence after ileocolic resection. Findings were evaluated by three radiologists, using an MR score based on image quality, contrast enhancement, and mural and extramural bowel-wall changes: MR0 (no abnormal features), MR1 (minimal mucosal changes), MR2 (diffuse aphtoid ileitis, moderate recurrence), and MR3 (severe recurrence with trans- and extramural changes). The endoscopic Rutgeerts score defines changes at the ileum on a scale from I0 to I4. In 3/30 (10%) patients, evaluation was not possible. The mean overall image quality was rated as 1.7 (kappa 0.78). Comparing MR and Rutgeerts score, the mean observer agreement for the total score rating was 77.8% (kappa 0.67). When comparing only scores below or above MR2—the threshold indicative of the necessity of medical treatment—there was a total agreement of 95.1% (kappa 0.84). MR enteroclysis allows assessment of Crohn’s disease recurrence after ileocolic resection. The MR score is reproducible and shows high agreement with the approved endoscopic Rutgeerts score.
引用
收藏
页码:2512 / 2521
页数:9
相关论文
共 105 条
[1]  
Przemioslo RT(1995)Pathogenesis of Crohn’s disease Q J Med 88 525-527
[2]  
Ciclitira PJ(2004)Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD Gastrointest Endosc 60 505-512
[3]  
Daperno M(1999)Surgical therapy for ulcerative colitis and Crohn’s disease Gastroenterol Clin North Am 28 371-390
[4]  
D’Haens G(1998)Early lesions of recurrent Crohn’s disease caused by infusion of intestinal excluded ileum Gastroenterology 114 262-267
[5]  
Van Assche G(1990)Predictability of the postoperative course of Crohn’s disease Gastroenterology 99 956-963
[6]  
Becker JM(2005)Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis J Manag Care Pharm 11 383-393
[7]  
D’Haens GR(2005)Sargramostim in Crohn’s disease study group. Sargramostim for active Crohn’s disease N Engl J Med 352 2193-2201
[8]  
Geboes K(2005)Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial Gastroenterology 128 856-861
[9]  
Peeters M(2001)MR enteroclysis imaging of Crohn disease Radiographics 21 161-172
[10]  
Baert F(2006)Assessment of Crohn’s disease in the small bowel: prospective comparison of magnetic resonance enteroclysis with conventional enteroclysis Eur Radiol 16 2817-2827